Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pola-ZR2P in Previously Untreated DLBCL
NCT06664411Phase 2Recruiting
- Start
- Sep 2024
- Primary completion
- Dec 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin, zanubrutinib and lenalidomide in diffuse large B-cell lymphoma (DLBCL). Primary endpoint: Progression Free Survival at 2 years. Started Sep 2024; status: recruiting.
02
Drugs
polatuzumab vedotinzanubrutiniblenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06664411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664411.